


**Disclosures under Regulation 29(1) of Securities and Exchange Board of India
(Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

Part-A- Details of the Acquisition

Name of the Target Company (TC)	SUVEN PHARMACEUTICALS LIMITED		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	<ol style="list-style-type: none"> 1. UTI Mutual Fund – Acquirer 2. Emirates Islamic India Equity Fund - PAC 3. JSS Responsible Equity India - PAC 4. K B India Growth Equity Fund - PAC 5. Shinsei UTI India Fund Class- A- PAC 6. UTI India Balance Fund - PAC 7. UTI India Dynamic Equity Fund - PAC 		
Whether the acquirer belongs to Promoter/Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited The National Stock Exchange of India Limited		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	1,26,31,620	4.9620	4.9620
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/others)			
c) Voting rights (VR) otherwise than by equity shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)			
e) Total (a + b + c + d)	1,26,31,620	4.9620	4.9620
Details of acquisition			
a) Shares carrying voting rights acquired	1,31,966	0.0518	0.0518
b) VRs acquired otherwise than by equity shares			
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying category) acquired			



d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/others)			
e) Total (a + b + c + d)	1,31,966	0.0518	0.0518
After the acquisition, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	1,27,63,586	5.0139	5.0139
b) VRs otherwise than by equity shares			
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition			
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/others)			
e) Total (a + b + c + d)	1,27,63,586	5.0139	5.0139
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer /encumbrance, etc.)	Secondary Market		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.			
Date of acquisition of/ date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	October 20, 2023		
Equity share capital / total voting capital of the TC before the said acquisition	Rs. 25,45,64,956		
Equity share capital/ total voting capital of the TC after the said acquisition	Rs. 25,45,64,956		
Total diluted share/voting capital of the TC after the said acquisition	Rs. 25,45,64,956		


Signature of the acquirer / Authorised Signatory

Place: Mumbai

Date: October 23, 2023



Part-B***

Name of the Target Company: SUVEN PHARMACEUTICALS LIMITED


Signature of the acquirer / Authorised Signatory



Place: Mumbai

Date: October 23, 2023

Note:

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(***) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.